Virus de Epstein-Barr y su relación con el desarrollo del cáncer

  • Angela Patricia Medina-Ortega Universidad del Cauca
  • David López-Valencia Universidad de Cauca
  • Sara Lucía Mosquera-Monje Universidad del Cauca
  • Diana Lorena Mora-Obando Universidad del Cauca
  • Rosa Amalia Dueñas-Cuéllar Universidad del Cauca
Palabras clave: Cáncer, Epstein-Barr, Herpes, Virus

Resumen

El virus de Epstein-Barr (VEB) es un agente infeccioso que tiene tropismo por células linfoides y ocasionalmente por células epiteliales. La Agencia Internacional para la Investigación sobre Cáncer (IARC, por su sigla en inglés) lo clasificó hace 20 años como carcinógeno de tipo I, porque durante la infección latente expresa diferentes proteínas o micro-ARN con capacidad oncogénica, por lo que las células infectadas tendrían el potencial de desarrollar cáncer. Esto se ha demostrado en algunos tipos de cáncer como linfomas, carcinoma nasofaríngeo y cáncer gástrico, mientras que la asociación no es completamente clara en los cánceres de mama y pulmón. La presente revisión describe, profundiza y analiza la relación del VEB con dichos tipos de cáncer, así como los métodos diagnósticos empleados para su detección. Finalmente, se plantean preguntas cuyas respuestas podrían contribuir al conocimiento de los mecanismos moleculares involucrados en la relación VEB-cáncer.

|Resumen
= 308 veces | PDF
= 233 veces| XHTML
= 0 veces|

Descargas

La descarga de datos todavía no está disponible.

Biografía del autor/a

Angela Patricia Medina-Ortega, Universidad del Cauca

Estudiante de Medicina en la Universidad del Cauca. Grupo de Investigación en Inmunología y Enfermedades Infecciosas, Facultad de Ciencias de la Salud, Universidad del Cauca, Popayán, Colombia.

David López-Valencia, Universidad de Cauca

Estudiante de Medicina en la Universidad del Cauca. Grupo de Investigación en Inmunología y Enfermedades Infecciosas, Facultad de Ciencias de la Salud, Universidad del Cauca, Popayán, Colombia.

Sara Lucía Mosquera-Monje, Universidad del Cauca

Estudiante de Medicina en la Universidad del Cauca. Grupo de Investigación en Inmunología y Enfermedades Infecciosas, Facultad de Ciencias de la Salud, Universidad del Cauca, Popayán, Colombia.

Diana Lorena Mora-Obando, Universidad del Cauca

Magister en Ciencias Biomédicas de la Universidad de Costa Rica, Docente tiempo completo del departamento de Patología de la Universidad del Cauca.

Rosa Amalia Dueñas-Cuéllar, Universidad del Cauca

Doctora en Ciencias Biológicas con énfasis en Biología molecular, docente tiempo completo del departamento de Patología de la Universidad del Cauca.

Citas

(1.) Song CG, Huang JJ, Li YJ, Xia Y, Wang Y, Bi XW, et al. Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma in the Elderly: A Matched Case-Control Analysis. PLoS One. 2015 Jul;10(7):e0133973. DOI 10.1371/journal.pone.0133973.

(2.) Karaarslan S, Hekimgil M, Soydan S, Ertan Y, Doğanavşargil B. Evaluation of the role of Epstein-Barr virus in cases of nodal or extranodal T- and NKcell lymphoma using eber in situ hybridization. Pol J Pathol. 2015 Jun;66(2):161-9.

(3.) King AM. Family – Herpesviridae. In: King AM, Adams MJ, Carstens EB, Lefkowitz EJ, editors. Virus taxonomy: Ninth report of the International Committee on Taxonomy of Viruses. London: Elsevier; 2011. p.111-22.

(4.) Rubin SD, Rubin E. Neoplasias. En: Rubin E, Rubin R, Strayer DS, editors. Patología de Rubin: Fundamentos Clinicopatológicos en Medicina. 6a ed. Philadelphia: Lippincott Williams and Wilkins, 2012. p. 200.

(5.) Grywalska E, Markowicz J, Grabarczyk P, Pasiarski M, Roliński J. Epstein-Barr virus-associated lymphoproliferative disorders. Postepy Hig Med Dosw (Online). 2013 May;67:481-90.

(6.) Levine H, Balicer RD, Rozhavski V, Halperin T, Shreberk M, Davidovitch N, et al. Seroepidemiology of Epstein-Barr virus and cytomegalovirus among Israeli male young adults. Ann Epidemiol. 2012 Nov;22(11):783-8. DOI 10.1016/j.annepidem.2012.06.099.

(7.) Kasper DL, Fauci AS, Hauser S, Longo D, Jameson L, Loscalzo J. Infections due to DNA viruses. In: Harrison’s Principles of Internal Medicine. 19th ed. New York City: McGraw Hill Professional; 2015. p. 1186-7.

(8.) Glaser SL, Hsu JL, Gulley ML. Epstein-Barr virus and breast cancer: state of the evidence for viral carcinogenesis. Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):688-97.

(9.) Jaramillo JM. Herpesvirus humanos. En: Díaz FJ, Estrada S, Franco L, Jaramillo JM, Maestre A, Ospina S, et al, editores. Microbiología de las infecciones humanas. Medellín: Corporación para Investigaciones Biológicas; 2007. p. 444-58.

(10.) Katano H, Ali MA, Patera AC, Catalfamo M, Jaffe ES, Kimura H, et al. Chronic active Epstein-Barr virus infection associated with mutations in perforin that impair its maturation. Blood. 2004 Feb;103(4):1244-52.

(11.) Brooks GF, Carroll KC, Butel JS, Morse SA, Mietzner TA. Herpesvirus. En: Microbiología médica. 25a ed. Nueva York: Mc Graw Hill; 2011. p. 450-2.

(12.) Cui Y, Wang Y, Liu X, Chao Y, Xing X, Zhao C, et al. Genotypic analysis of Epstein-Barr virus isolates associated with nasopharyngeal carcinoma in Northern China. Intervirology. 2011;54(3):131-8. DOI 10.1159/000319632.

(13.) Zur Hausen H, Schulte-Holthausen H, Klein G, Henle G, Henle W, Clifford P, et al. Epstein-Barr virus in Burkitt’s lymphoma and nasopharyngeal carcinoma.[ii] EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature. 1970;228:1056-8. DOI 10.1038/2281056a0.

(14.) World Health Organization, International Agency for Research on Cancer. The monographs, Epstein-Barr virus. In: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Epstein-Barr virus and Kaposi’s sarcoma herpesvirus/human herpesvirus 8. Vol. 70. Lyon: WHO; 1997. p. 47-373.

(15.) Murray PR, Pfaüer M. Virus herpes humanos. En: Murray RP. Microbiología médica. 7a ed. Philadelphia: Elsevier; 2014. p. 461-77.

(16.) Woellmer A, Hammerschmidt W. Epstein-Barr virus and host cell methylation: regulation of latency, replication and virus reactivation. Curr Opin Virol. 2013 Jun;3(3):260-5. DOI 10.1016/j.coviro.2013.03.005.

(17.) Ferrajoli A, Ivan C, Ciccone M, Shimizu M, Kita Y, Ohtsuka M, et al. Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival. EBioMedicine. 2015 Apr;2(6):572-82. DOI 10.1016/j.ebiom.2015.04.018.

(18.) Lin SJ, Wu SW, Chou YC, Lin JH, Huang YC, Chen MR, et al. Novel expression and regulation of TIMP-1 in Epstein Barr virus-infected cells and its impact on cell survival. Virology. 2015 Jul;481:24-33. DOI 10.1016/j.virol.2015.02.015.

(19.) Kondo S, Wakisaka N, Muramatsu M, Zen Y, Endo K, Murono S, et al. Epstein-Barr virus latent membrane protein 1 induces cancer stem/progenitor-like cells in nasopharyngeal epithelial cell lines. J Virol. 2011 Nov;85(21):11255-64. DOI 10.1128/JVI.00188-11.

(20.) Kong QL, Hu LJ, Cao JY, Huang YJ, Xu LH, Liang Y, et al. Epstein-Barr virus-encoded LMP2A induces an epithelial-mesenchymal transition and increases the number of side population stem-like cancer cells in nasopharyngeal carcinoma. PLoS Pathog. 2010 Jun;6(6):e1000940. DOI 10.1371/journal.ppat.1000940.

(21.) Deb Pal A, Banerjee S. Epstein-Barr virus latent membrane protein 2A mediated activation of Sonic Hedgehog pathway induces HLA class Ia downregulation in gastric cancer cells. Virology. 2015 Oct;484:22-32. DOI 10.1016/j.virol.2015.05.007.

(22.) Middeldorp JM, Brink AA, van den Brule AJ, Meijer CJ. Pathogenic roles for Epstein-Barr virus (EBV) gene products in EBV-associated proliferative disorders. Crit Rev Oncol Hematol. 2003 Jan;45(1):1-36.

(23.) Saha A, Robertson ES. Epstein-Barr virus-associated B-cell lymphomas: pathogenesis and clinical outcomes. Clin Cancer Res. 2011 May;17(10):3056-63. DOI 10.1158/1078-0432.CCR-10-2578.

(24.) Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from burkitt’s lymphoma. Lancet. 1964 Mar;1(7335):702-3.

(25.) Epstein MA, Henle G, Achong BG, Barr YM. Morphological and biological studies on a virus in cultured lymphoblasts from Burkitt’s lymphoma. J Exp Med. 1965 May;121:761-70.

(26.) Weiss LM, Strickler JG, Warnke RA, Purtilo DT, Sklar J. Epstein-Barr viral DNA in tissues of Hodgkin’s disease. Am J Pathol. 1987 Oct;129(1):86-91.

(27.) Levine PH, Pallesen G, Ebbesen P, Harris N, Evans AS, Müeller N. Evaluation of Epstein-Barr virus antibody patterns and detection of viral markers in the biopsies of patients with Hodgkin’s disease. Int J Cancer. 1994 Oct;59(1):48-50.

(28.) Glaser SL, Lin RJ, Stewart SL, Ambinder RF, Jarrett RF, Brousset P, et al. Epstein-Barr virus-associated Hodgkin’s disease: epidemiologic characteristics in international data. Int J Cancer. 1997 Feb;70(4):375-82.

(29.) Nie Y, Sun Y, Wang Y, Liu C, Zhao C, Luo B. Epstein-Barr virus gene polymorphism in different parts of the same nasopharyngeal carcinoma patient. Arch Virol. 2013 May;158(5):1031-7. DOI 10.1007/s00705-012-1578-2.

(30.) Longo DL. Neoplasias malignas de las células linfoides. En: Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J. Harrison. Principios de Medicina Interna. 18a ed. New York City: McGraw Hill Professional; 2013. p. 919- 21.

(31.) Levy JA. El VIH y el desarrollo del cáncer. En: El VIH y la patogénesis del SIDA. México: Fondo De Cultura Económica; 2008. p. 365.

(32.) Lenze D, Leoncini L, Hummel M, Volinia S, Liu CG, Amato T, et al. The diferente epidemiologic subtypes of Burkitt lymphoma share a homogenous micro RNA profile distinct from diffuse large B-cell lymphoma. Leukemia. 2011 Dec;25(12):1869-76. DOI 10.1038/leu.2011.156.

(33.) Rowe M, Fitzsimmons L, Bell AI. Epstein-Barr virus and Burkitt lymphoma. Chin J Cancer. 2014 Dec;33(12):609-19. DOI 10.5732/cjc.014.10190.

(34.) Cordier M, Calender A, Billaud M, Zimber U, Rousselet G, Pavlish O, et al. Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23. J Virol. 1990 Mar;64(3):1002-13.

(35.) Thompson MP, Aggarwal BB, Shishodia S, Estrov Z, Kurzrock R. Autocrine lymphotoxin production in Epstein-Barr virus-immortalized B cells: induction via NF-kappaB activation mediated by EBV-derived latent membrane protein 1. Leukemia. 2003 Nov;17(11):2196-201.

(36.) Grywalska E, Rolinski J. Epstein-Barr virus-associated lymphomas. Semin Oncol. 2015 Apr;42(2):291-303. DOI 10.1053/j.seminoncol.2014.12.030.

(37.) Schwemmle M, Clemens MJ, Hilse K, Pfeifer K, Tröster H, Müller WE, et al. Localization of Epstein-Barr virusencoded RNAs EBER-1 and EBER-2 in interphase and mitotic Burkitt lymphoma cells. Proc Natl Acad Sci U S A. 1992 Nov;89(21):10292-6.

(38.) Spano JP, Busson P, Atlan D, Bourhis J, Pignon JP, Esteban C, et al. Nasopharyngeal carcinomas: an update. Eur J Cancer. 2003 Oct;39(15):2121-35.

(39.) Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar;136(5):E359-86. DOI 10.1002/ijc.29210.

(40.) Henle W, Henle G, Ho HC, Burtin P, Cachin Y, Clifford P, et al. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, other head and neck neoplasms, and control groups. J Natl Cancer Inst. 1970 Jan;44(1):225-31.

(41.) Chiang AK, Tao Q, Srivastava G, Ho FC. Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin’s disease. Int J Cancer. 1996 Nov 4;68(3):285-90.

(42.) Brooks L, Yao QY, Rickinson AB, Young LS. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol. 1992 May;66(5):2689-97.

(43.) Fåhraeus R, Fu HL, Ernberg I, Finke J, Rowe M, Klein G, et al. Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer. 1988 Sep;42(3):329-38.

(44.) Young LS, Dawson CW, Clark D, Rupani H, Busson P, Tursz T, et al. Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol. 1988 May;69 (Pt 5):1051-65.

(45.) Wu TC, Mann RB, Epstein JI, MacMahon E, Lee WA, Charache P, et al. Abundant expression of EBER1 small nuclear RNA in nasopharyngeal carcinoma. A morphologically distinctive target for detection of Epstein-Barr virus in formalin-fixed paraffin-embedded carcinoma specimens. Am J Pathol. 1991 Jun;138(6):1461-9.

(46.) Matalka I, Al Hamad M, Al-Hussaini M, Alzoubi FQ. The incidence of Epstein-Barr virus in nasopharyngeal carcinoma of Jordanian patients. Eur Arch Otorhinolaryngol. 2012 Jan;269(1):229-34. DOI 10.1007/s00405-011-1562-6.

(47.) Lin SY, Tsang NM, Kao SC, Hsieh YL, Chen YP, Tsai CS, et al. Presence of Epstein-Barr virus latent membrane protein 1 gene in the nasopharyngeal swabs from patients with nasopharyngeal carcinoma. Head Neck. 2001 Mar;23(3):194-200.

(48.) Sarac S, Akyol MU, Kanbur B, Poyraz A, Akyol G, Yilmaz T, et al. Bcl-2 and LMP1 expression in nasopharyngeal carcinomas. Am J Otolaryngol. 2001 Nov-Dec;22(6):377-82.

(49.) Pathmanathan R, Prasad U, Sadler R, Flynn K, Raab-Traub N. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med. 1995 Sep;333(11):693-8.

(50.) Tsao SW, Tramoutanis G, Dawson CW, Lo AK, Huang DP. The significance of LMP1 expression in nasopharyngeal carcinoma. Semin Cancer Biol. 2002 Dec;12(6):473-87.

(51.) Tsao SW, Wang X, Liu Y, Cheung YC, Feng H, Zheng Z, et al. Establishment of two immortalized nasopharyngeal epithelial cell lines using SV40 large T and HPV16E6/E7 viral oncogenes. Biochim Biophys Acta. 2002 Jun;1590(1-3):150-8.

(52.) Wang D, Liebowitz D, Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell. 1985 Dec;43(3 Pt 2):831-40.

(53.) Horikawa T, Yoshizaki T, Sheen TS, Lee SY, Furukawa M. Association of latent membrane protein 1 and matrix metalloproteinase 9 with metastasis in nasopharyngeal carcinoma. Cancer. 2000 Aug;89(4):715-23.

(54.) Endo K, Kondo S, Shackleford J, Horikawa T, Kitagawa N, Yoshizaki T, et al. Phosphorylated ezrin is associated with EBV latent membrane protein 1 in nasopharyngeal carcinoma and induces cell migration. Oncogene. 2009 Apr;28(14):1725-35. DOI 10.1038/onc.2009.20.

(55.) Zheng Z, Pan J, Chu B, Wong YC, Cheung AL, Tsao SW. Downregulation and abnormal expression of Ecadherin and beta-catenin in nasopharyngeal carcinoma: close association with advanced disease stage and lymph node metastasis. Hum Pathol. 1999 Apr;30(4):458-66.

(56.) Hui EP, Chan AT, Pezzella F, Turley H, To KF, Poon TC, et al. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res. 2002 Aug;8(8):2595-604.

(57.) Kitagawa N, Kondo S, Wakisaka N, Zen Y, Nakanishi Y, Tsuji A, et al. Expression of seven-in-absentia homologue 1 and hypoxia-inducible factor 1 alpha: novel prognostic factors of nasopharyngeal carcinoma. Cancer Lett. 2013 Apr;331(1):52-7. DOI 10.1016/j.canlet.2012.12.002.

(58.) Decaussin G, Sbih-Lammali F, de Turenne-Tessier M, Bouguermouh A, Ooka T. Expression of BARF1 gene encoded by Epstein-Barr virus in nasopharyngeal carcinoma biopsies. Cancer Res. 2000 Oct;60(19):5584-8.

(59.) Labrecque LG, Barnes DM, Fentiman IS, Griffin BE. Epstein-Barr virus in epithelial cell tumors: a breast cancer study. Cancer Res. 1995 Jan;55(1):39-45.

(60.) Bonnet M, Guinebretiere JM, Kremmer E, Grunewald V, Benhamou E, Contesso G, et al. Detection of Epstein-Barr virus in invasive breast cancers. J Natl Cancer Inst. 1999 Aug;91(16):1376-81.

(61.) Glenn WK, Heng B, Delprado W, Iacopetta B, Whitaker NJ, Lawson JS. Epstein-Barr virus, human papillomavirus and mouse mammary tumour virus as multiple viruses in breast cancer. PLoS One. 2012;7(11):e48788. DOI 10.1371/journal.pone.0048788.

(62.) Zekri AR, Bahnassy AA, Mohamed WS, El-Kassem FA, El-Khalidi SJ, Hafez MM, et al. Epstein-Barr virus and breast cancer: epidemiological and molecular study on Egyptian and Iraqi women. J Egypt Natl Canc Inst. 2012 Sep;24(3):123-31. DOI 10.1016/j.jnci.2012.06.001.

(63.) Mazouni C, Fina F, Romain S, Ouafik L, Bonnier P, Martin PM. Outcome of Epstein-Barr virus-associated primary breast cancer. Mol Clin Oncol. 2015 Mar;3(2):295-8.

(64.) Fina F, Romain S, Ouafik L, Palmari J, Ben Ayed F, Benharkat S, et al. Frequency and genome load of Epstein-Barr virus in 509 breast cancers from different geographical areas. Br J Cancer. 2001 Mar;84(6):783-90.

(65.) Khabaz MN. Association of Epstein-Barr virus infection and breast carcinoma. Arch Med Sci. 2013 Aug;9(4):745-51. DOI 10.5114/aoms.2013.37274.

(66.) Herrmann K, Niedobitek G. Lack of evidence for an association of Epstein-Barr virus infection with breast carcinoma. Breast Cancer Res. 2003;5(1):R13-7.

(67.) Murray PG, Lissauer D, Junying J, Davies G, Moore S, Bell A, et al. Reactivity with A monoclonal antibody to Epstein-Barr virus (EBV) nuclear antigen 1 defines a subset of aggressive breast cancers in the absence of the EBV genome. Cancer Res. 2003 May;63(9):2338-43.

(68.) Khan G, Philip PS, Al Ashari M. Is Epstein-Barr virus associated with aggressive forms of breast cancer? Br J Cancer. 2011 Apr;104(8):1362-3; author reply 1364. DOI 10.1038/bjc.2011.99.

(69.) Magrath I, Bhatia K. Breast cancer: a new Epstein-Barr virus-associated disease? J Natl Cancer Inst. 1999 Aug;91(16):1349-50.

(70.) Lin JH, Tsai CH, Chu JS, Chen JY, Takada K, Shew JY. Dysregulation of HER2/HER3 signaling axis in Epstein-Barr virus-infected breast carcinoma cells. J Virol. 2007 Jun;81(11):5705-13.

(71.) IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1-441.

(72.) Cárdenas-Mondragón MG, Carreón-Talavera R, Camorlinga-Ponce M, Gomez-Delgado A, Torres J, Fuentes-Pananá EM. Epstein Barr virus and Helicobacter pylori co-infection are positively associated with severe gastritis in pediatric patients. PLoS One. 2013 Apr;8(4):e62850. DOI 10.1371/journal.pone.0062850.

(73.) Burke AP, Yen TS, Shekitka KM, Sobin LH. Lymphoepithelial carcinoma of the stomach with Epstein-Barr virus demonstrated by polymerase chain reaction. Mod Pathol. 1990 May;3(3):377-80.

(74.) Hsieh LL, Lin PJ, Chen TC, Ou JT. Frequency of Epstein-Barr virus-associated gastric adenocarcinoma in Taiwan. Cancer Lett. 1998 Jul;129(2):125-9.

(75.) Truong CD, Feng W, Li W, Khoury T, Li Q, Alrawi S, et al. Characteristics of Epstein-Barr virus-associated gastric cancer: a study of 235 cases at a comprehensive cancer center in U.S.A. J Exp Clin Cancer Res. 2009 Feb;28:14. DOI 10.1186/1756-9966-28-14.

(76.) Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014 Sep;513(7517):202-9. DOI 10.1038/nature13480.

(77.) Abe H, Kaneda A, Fukayama M. Epstein-Barr Virus-Associated Gastric Carcinoma: Use of Host Cell Machineries and Somatic Gene Mutations. Pathobiology. 2015;82(5):212-23. DOI 10.1159/000434683.

(78.) Torlakovic G, Snover DC, Torlakovic E. Simultaneous EBV-positive lymphoepithelioma-like carcinoma and EBV-negative intestinal-type adenocarcinoma in a patient with Helicobacter pylori-associated chronic gastritis. Am J Clin Pathol. 2004 Feb;121(2):237-43.

(79.) Uozaki H, Fukayama M. Epstein-Barr virus and gastric carcinoma—viral carcinogenesis through epigenetic mechanisms. Int J Clin Exp Pathol. 2008 Jan;1(3):198-216.

(80.) Camargo MC, Murphy G, Koriyama C, Pfeiffer RM, Kim WH, Herrera-Goepfert R, et al. Determinants of Epstein-Barr virus-positive gastric cancer: an international pooled analysis. Br J Cancer. 2011 Jun;105(1):38-43. DOI 10.1038/bjc.2011.215.

(81.) Akiba S, Koriyama C, Herrera-Goepfert R, Eizuru Y. Epstein-Barr virus associated gastric carcinoma: epidemiological and clinicopathological features. Cancer Sci. 2008 Feb;99(2):195-201. DOI 10.1111/j.1349-7006.2007.00674.x.

(82.) Lee JH, Kim SH, Han SH, An JS, Lee ES, Kim YS. Clinicopathological and molecular characteristics of Epstein-Barr virus-associated gastric carcinoma: a meta-analysis. J Gastroenterol Hepatol. 2009 Mar;24(3):354-65. DOI 10.1111/j.1440-1746.2009.05775.x.

(83.) Fukayama M, Hino R, Uozaki H. Epstein-Barr virus and gastric carcinoma: virus-host interactions leading to carcinoma. Cancer Sci. 2008 Sep;99(9):1726-33. DOI 10.1111/j.1349-7006.2008.00888.x.

(84.) Carrascal E, Tokunaga M, Akiba S, Eizuru Y, Fujiyama C, Shinkura R, et al. Adenocarcinoma gástrico asociado con el virus de Epstein-Barr en Cali. Colomb Méd. 2014;30(3):127-31.

(85.) Liu X, Liu J, Qiu H, Kong P, Chen S, Li W, et al. Prognostic significance of Epstein-Barr virus infection in gastric cancer: a meta-analysis. BMC Cancer. 2015 Oct;15:782. DOI 10.1186/s12885-015-1813-9.

(86.) Chen JN, Jiang Y, Li HG, Ding YG, Fan XJ, Xiao L, et al. Epstein-Barr virus genome polymorphisms of Epstein-Barr virus-associated gastric carcinoma in gastric remnant carcinoma in Guangzhou, southern China, an endemic area of nasopharyngeal carcinoma. Virus Res. 2011 Sep;160(1-2):191-9. DOI 10.1016/j.virusres.2011.06.011.

(87.) Gulley ML. Genomic assays for Epstein-Barr viruspositive gastric adenocarcinoma. Exp Mol Med. 2015 Jan;47:e134. DOI 10.1038/emm.2014.93.

(88.) Saadat I, Higashi H, Obuse C, Umeda M, Murata-Kamiya N, Saito Y, et al. elicobacter pylori CagA targets PAR1/MARK kinase to disrupt epithelial cell polarity. Nature. 2007 May;447(7142):330-3.

(89.) Lee HH, Chang SS, Lin SJ, Chua HH, Tsai TJ, Tsai K, et al. Essential role of PKCdelta in histone deacetylase inhibitor-induced Epstein-Barr virus reactivation in nasopharyngeal carcinoma cells. J Gen Virol. 2008 Apr;89(Pt 4):878-83. DOI 10.1099/vir.0.83533-0.

(90.) Shukla SK, Prasad KN, Tripathi A, Singh A, Saxena A, Ghoshal UC, et al. Epstein-Barr virus DNA load and its association with Helicobacter pylori infection in gastroduodenal diseases. Braz J Infect Dis. 2011 Nov-Dec;15(6):583-90.

(91.) Minoura-Etoh J, Gotoh K, Sato R, Ogata M, Kaku N, Fujioka T, et al. Helicobacter pylori-associated oxidant monochloramine induces reactivation of Epstein-Barr virus (EBV) in gastric epithelial cells latently infected with EBV. J Med Microbiol. 2006 Jul;55(Pt 7):905-11.

(92.) Bégin LR, Eskandari J, Joncas J, Panasci L. Epstein-Barr virus related lymphoepithelioma-like carcinoma of lung. J Surg Oncol. 1987 Dec;36(4):280-3.

(93.) Tsujimoto Y. Overexpression of the human BCL-2 gene product results in growth enhancement of Epstein-Barr virus-immortalized B cells. Proc Natl Acad Sci U S A. 1989 Mar;86(6):1958-62.

(94.) Chen FF, Yan JJ, Lai WW, Jin YT, Su IJ. Epstein-Barr virus-associated nonsmall cell lung carcinoma: undifferentiated “lymphoepithelioma-like” carcinoma as a distinct entity with better prognosis. Cancer. 1998 Jun;82(12):2334-42.

(95.) Iezzoni JC, Gaffey MJ, Weiss LM. The role of Epstein-Barr virus in lymphoepithelioma-like carcinomas. Am J Clin Pathol. 1995 Mar;103(3):308-15.

(96.) Castro CY, Ostrowski ML, Barrios R, Green LK, Popper HH, Powell S, et al. Relationship between Epstein-Barr virus and lymphoepithelioma-like carcinoma of the lung: a clinicopathologic study of 6 cases and review of the literature. Hum Pathol. 2001 Aug;32(8):863-72.

(97.) Chu PG, Cerilli L, Chen YY, Mills SE, Weiss LM. Epstein-Barr virus plays no role in the tumorigenesis of small-cell carcinoma of the lung. Mod Pathol. 2004 Feb;17(2):158-64.

(98.) Koshiol J, Gulley ML, Zhao Y, Rubagotti M, Marincola FM, Rotunno M, et al. Epstein-Barr virus microRNAs and lung cancer. Br J Cancer. 2011 Jul;105(2):320-6. DOI 10.1038/bjc.2011.221.

(99.) Jafarian AH, Omidi-Ashrafi A, Mohamadian-Roshan N, Karimi-Shahri M, Ghazvini K, Boroumand-Noughabi S. Association of Epstein Barr virus deoxyribonucleic acid with lung carcinoma. Indian J Pathol Microbiol. 2013 Oct-Dec;56(4):359-64. DOI 10.4103/0377-4929.125290.

(100.) Nishino R, Takano A, Oshita H, Ishikawa N, Akiyama H, Ito H, et al. Identification of Epstein-Barr virus-induced gene 3 as a novel serum and tissue biomarker and a therapeutic target for lung cancer. Clin Cancer Res. 2011 Oct;17(19):6272-86. DOI 10.1158/1078-0432.CCR-11-0060.

(101.) Gutiérrez MI, Judde JG, Magrath IT, Bhatia KG. Switching viral latency to viral lysis: a novel therapeutic approach for Epstein-Barr virus-associated neoplasia. Cancer Res. 1996 Mar;56(5):969-72.

Publicado
2017-04-11
Cómo citar
1.
Medina-Ortega AP, López-Valencia D, Mosquera-Monje SL, Mora-Obando DL, Dueñas-Cuéllar RA. Virus de Epstein-Barr y su relación con el desarrollo del cáncer. Iatreia [Internet]. 11 de abril de 2017 [citado 25 de septiembre de 2021];30(2):131-45. Disponible en: https://revistas.udea.edu.co/index.php/iatreia/article/view/25886
Sección
Artículos de revisión